President and Chairman of the Board of Directors, Anil R. Diwan, Ph.D., of NanoViricides, Inc., Discusses Company Updates with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
Aug. 21, 2018
PHOENIX, Aug. 21, 2018 (GLOBE NEWSWIRE) -- NanoViricides, Inc. (NYSE:NNVC), (the “Company”) announced President and Chairman, Dr. Anil Diwan’s interview on Uptick Newswire’s “Stock Day” Podcast.
Everett Jolly invited NanoViricides, Inc.’s President and Chairman of the Board of Directors, Anil R. Diwan, Ph.D., back for the first time in over a year to the “Stock Day” podcast for an update.
“Dr. Diwan, I know that you founded the Company in 2005 and you’re getting close to some clinical trials. I just want you to give an update of what’s going on.”
Since uplisting to NYSE-American, the Company has raised over $45 million and have been single-focused on the HerpeCide™ program and they are very excited about their progress in moving forward for clinical trials. They already completed the preliminary safety toxicology study on their main drug candidate. The Company has the ability to make their materials in multi-kilogram quantities and so they are now in a position to file an IND, an Investigational New Drug Application.
NanoViricides, Inc., has a new CEO starting on September 1, 2018, who is a seasoned pharmaceutical executive with over 25 years of experience in drug development and regulatory strategy. Dr. Irach B. Taraporewala is a hands-on CEO with a strong scientific background combined with significant management, leadership, business development and financing experience.
Dr. Diwan believes that the Company will have multiple drugs in clinical trials within the next few years. He further indicated that they have sufficient financing in place to move forward with the first drug. He said they plan to go back to the market at the appropriate time. In getting great test results, they’ll be able to get a better market and be able to raise money with much less dilution. The Company doesn’t necessarily want to market products on their own, but plans to look into partnerships.
He believes they are at an inflection point right now with the first drug candidate, and wanted to point out that they are not a single-drug company. They have three different drug candidates that are ready to go as they raise money. So, just based on the assessments they’ve done to date, they have a very bright future. It’s a broad and deep pipeline. They’re getting very close to that one drug that will change the industry.
For more information about the Company’s financial details, listen to the full interview at the link below:
About NanoViricides, Inc.NanoViricides, Inc. (the "Company"), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a development stage company with several drugs in various stages of early development, based on a unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines that we call “nanoviricides®.” Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. seasonal and potentially-epidemic influenzas and bird flu, HIV/AIDS, HSV-1 “cold sores” and HSV-2 genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness. Nanoviricides are designed to complete the task of dismantling the virus particle without immune system assistance. Thus, nanoviricides represent the next great advance in “Immunotherapeutics.”
Safe Harbor Act and Forward-Looking StatementsThis press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.
Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
About Uptick Newswire and the “Stock Day” PodcastFounded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
SOURCE:Uptick Newswire https://upticknewswire.com/